MA43052B1 - Inhibiteurs de la kallicréine plasmatique humaine - Google Patents

Inhibiteurs de la kallicréine plasmatique humaine

Info

Publication number
MA43052B1
MA43052B1 MA43052A MA43052A MA43052B1 MA 43052 B1 MA43052 B1 MA 43052B1 MA 43052 A MA43052 A MA 43052A MA 43052 A MA43052 A MA 43052A MA 43052 B1 MA43052 B1 MA 43052B1
Authority
MA
Morocco
Prior art keywords
plasma kallikrein
human plasma
kallikrein inhibitors
compounds
relates
Prior art date
Application number
MA43052A
Other languages
English (en)
Other versions
MA43052A (fr
Inventor
Pravin Kotian
Yarlagadda Babu
V Kumar
Weihe Zhang
Lakshminarayana Vogeti
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MA43052A publication Critical patent/MA43052A/fr
Publication of MA43052B1 publication Critical patent/MA43052B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des composés de la formule (i), et leurs sels pharmaceutiquement acceptables. Les composés sont des inhibiteurs de la kallicréine plasmatique. L'invention concerne également des compositions pharmaceutiques comprenant au moins un composé selon l'invention, et des méthodes impliquant l'utilisation des composés et des compositions selon l'invention pour le traitement et la prévention de maladies et de pathologies caractérisées par une activité indésirable de la kallicréine plasmatique.
MA43052A 2015-10-01 2016-09-30 Inhibiteurs de la kallicréine plasmatique humaine MA43052B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235754P 2015-10-01 2015-10-01
PCT/US2016/054619 WO2017059178A1 (fr) 2015-10-01 2016-09-30 Inhibiteurs de la kallicréine plasmatique humaine

Publications (2)

Publication Number Publication Date
MA43052A MA43052A (fr) 2021-05-12
MA43052B1 true MA43052B1 (fr) 2021-11-30

Family

ID=58424336

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43052A MA43052B1 (fr) 2015-10-01 2016-09-30 Inhibiteurs de la kallicréine plasmatique humaine

Country Status (31)

Country Link
US (3) US10562850B2 (fr)
EP (2) EP3355890B1 (fr)
JP (2) JP6916171B2 (fr)
KR (1) KR102696432B1 (fr)
CN (2) CN108289893B (fr)
AR (1) AR106241A1 (fr)
AU (2) AU2016330926B2 (fr)
CA (1) CA2999164A1 (fr)
CO (1) CO2018004572A2 (fr)
CY (1) CY1124907T1 (fr)
DK (2) DK3355890T3 (fr)
EA (2) EA038492B1 (fr)
ES (2) ES2985200T3 (fr)
FI (1) FI4019022T3 (fr)
HR (2) HRP20220059T1 (fr)
HU (2) HUE066999T2 (fr)
IL (3) IL291268B2 (fr)
LT (2) LT3355890T (fr)
MA (1) MA43052B1 (fr)
MD (1) MD3355890T2 (fr)
MX (2) MX385687B (fr)
MY (1) MY198346A (fr)
PH (2) PH12022550143A1 (fr)
PL (2) PL4019022T3 (fr)
PT (2) PT4019022T (fr)
RS (2) RS65443B1 (fr)
SG (1) SG10202003705WA (fr)
SI (2) SI3355890T1 (fr)
SM (2) SMT202400111T1 (fr)
TW (2) TWI734702B (fr)
WO (1) WO2017059178A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4019022T3 (fi) * 2015-10-01 2024-04-19 Biocryst Pharm Inc Ihmisen plasman kallikreiinin estäjiä
EP4494698A3 (fr) * 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibiteurs de la kallicréine plasmatique et leurs utilisations
EP3841086B1 (fr) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médicaux liés au facteur d du complément
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
CN110938077B (zh) * 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
CN115362256A (zh) 2020-02-07 2022-11-18 因特利亚治疗公司 用于激肽释放酶（klkb1）基因编辑的组合物和方法
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CN116444485B (zh) * 2023-03-30 2024-01-23 广西中医药大学 吡啶基取代不对称脲的非金属催化、免柱层析合成方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (fr) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Support pour medicaments a liberation progressive
EP0470246B1 (fr) 1990-02-28 1995-06-28 Medtronic, Inc. Prothese pour l'elution intraluminale d'un medicament
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
CA2170030A1 (fr) * 1993-09-14 1995-03-23 Robert A. Lazarus Compositions pharmaceutiques renfermant de l'ecotine et leurs homologues
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
WO1998006694A1 (fr) * 1996-08-16 1998-02-19 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines et -isoxazolidines et leurs derives
EP1217000A1 (fr) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibiteurs du factor Xa et factor VIIa
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
DE10315377A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Carbonylverbindungen
PL377633A1 (pl) * 2003-04-03 2006-02-06 Merck Patent Gmbh Związki karbonylowe
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
US20140350034A1 (en) 2012-01-27 2014-11-27 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
EP3095786A4 (fr) * 2014-01-14 2017-10-11 Sumitomo Dainippon Pharma Co., Ltd. Dérivé condensé de 5-oxazolidinone
HRP20221373T1 (hr) * 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
FI4019022T3 (fi) * 2015-10-01 2024-04-19 Biocryst Pharm Inc Ihmisen plasman kallikreiinin estäjiä

Also Published As

Publication number Publication date
SI3355890T1 (sl) 2022-04-29
BR112018005843A2 (pt) 2018-10-16
TWI734702B (zh) 2021-08-01
US11066360B2 (en) 2021-07-20
EA201890862A1 (ru) 2018-10-31
FI4019022T3 (fi) 2024-04-19
SMT202400111T1 (it) 2024-05-14
HRP20220059T1 (hr) 2022-04-15
HRP20240557T8 (hr) 2024-09-27
US20180362458A1 (en) 2018-12-20
RS65443B1 (sr) 2024-05-31
PL3355890T3 (pl) 2022-02-21
DK3355890T3 (da) 2022-01-03
PH12022550143A1 (en) 2022-11-21
CY1124907T1 (el) 2023-01-05
MX2021010297A (es) 2021-10-22
US20200361867A1 (en) 2020-11-19
JP2021169505A (ja) 2021-10-28
MA43052A (fr) 2021-05-12
AU2016330926B2 (en) 2021-04-29
EP4019022A1 (fr) 2022-06-29
KR20180058815A (ko) 2018-06-01
MY198346A (en) 2023-08-28
PT4019022T (pt) 2024-03-11
CN108289893B (zh) 2022-04-12
DK4019022T3 (en) 2024-02-19
IL291268B2 (en) 2023-12-01
PL4019022T3 (pl) 2024-06-24
PH12018500678A1 (en) 2018-10-01
EP3355890B1 (fr) 2021-11-10
US10562850B2 (en) 2020-02-18
EP3355890A1 (fr) 2018-08-08
AR106241A1 (es) 2017-12-27
SG10202003705WA (en) 2020-06-29
NZ741030A (en) 2024-12-20
EA202191548A1 (ru) 2021-09-02
IL281066A (en) 2021-04-29
CN114591212A (zh) 2022-06-07
SI4019022T1 (sl) 2024-06-28
PT3355890T (pt) 2022-01-19
TWI796714B (zh) 2023-03-21
IL281066B (en) 2022-04-01
WO2017059178A1 (fr) 2017-04-06
HUE057106T2 (hu) 2022-04-28
EA038492B1 (ru) 2021-09-07
TW201716381A (zh) 2017-05-16
LT4019022T (lt) 2024-03-25
MX385687B (es) 2025-03-18
CN108289893A (zh) 2018-07-17
AU2021201924B2 (en) 2022-10-13
IL291268A (en) 2022-05-01
US11807605B2 (en) 2023-11-07
JP2018529721A (ja) 2018-10-11
EP3355890A4 (fr) 2019-04-24
HK1254865A1 (en) 2019-07-26
US20220098151A1 (en) 2022-03-31
HUE066999T2 (hu) 2024-10-28
EP4019022B1 (fr) 2024-01-31
JP7431778B2 (ja) 2024-02-15
IL291268B1 (en) 2023-08-01
CA2999164A1 (fr) 2017-04-06
TW202136212A (zh) 2021-10-01
MX2018003930A (es) 2018-09-18
AU2016330926A1 (en) 2018-04-26
RS62807B1 (sr) 2022-02-28
ES2985200T3 (es) 2024-11-04
CN114591212B (zh) 2025-01-28
HRP20240557T1 (hr) 2024-07-05
SMT202200075T1 (it) 2022-03-21
LT3355890T (lt) 2021-12-27
IL258104A (en) 2018-05-31
IL258104B (en) 2021-03-25
MD3355890T2 (ro) 2022-03-31
KR102696432B1 (ko) 2024-08-16
JP6916171B2 (ja) 2021-08-11
AU2021201924A1 (en) 2021-04-29
CO2018004572A2 (es) 2018-10-31
ES2905401T3 (es) 2022-04-08

Similar Documents

Publication Publication Date Title
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA51627B1 (fr) Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés
EP4371562A3 (fr) Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
EA202192433A1 (ru) Соединения, полезные в терапии вич
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
PH12021550304A1 (en) Novel medicament for treating inflammatory bowel disease
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA35010B1 (fr) Inhibiteurs de la peptide déformylase
MA39719B1 (fr) Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine
FR3028762B1 (fr) Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
MA52370B1 (fr) Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6
NZ800047A (en) Benzimidazolone derived inhibitors of bcl6